1. Clinical & Scientific Overview
Cabergoline & Desmopressin Acetate (TIP-MED-000102, Reference Code [6.12]) is classified under
Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06) as a Ergot-Derived Dopamine D2 Receptor Agonist & Synthetic Vasopressin (V2) Analogue (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 06 [6.12], p. 77): Cabergoline: Cabgolin (Sun), Dostinex (Pfizer), Camforte. Desmopressin: Minirin / Minirin Melt (Ferring), Dpressin — Strengths & Dosage Forms: Cabergoline Tablets: 0.25 mg, 0.5 mg. Desmopressin Tablets: 0.1 mg (100 mcg), 0.2 mg (200 mcg); Sublingual Melt: 60 mcg, 120 mcg; Nasal Spray: 10 mcg/spray
Cabergoline Tablets: 0.25 mg, 0.5 mg. Desmopressin Tablets: 0.1 mg (100 mcg), 0.2 mg (200 mcg); Sublingual Melt: 60 mcg, 120 mcg; Nasal Spray: 10 mcg/spray
3. Mechanism of Action & Pharmacodynamics
Ergot-Derived Dopamine D2 Receptor Agonist & Synthetic Vasopressin (V2) Analogue (Schedule H) acting on target receptor/enzyme pathways in Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06): clinical efficacy is mediated via Ergot-Derived Dopamine D2 Receptor Agonist & Synthetic Vasopressin (V2) Analogue (Schedule H) for Cabergoline: Hyperprolactinaemia, prolactinoma (pituitary micro/macroadenoma), and inhibition/suppression of physiological lactation. Desmopressin: Central Diabetes Insipidus (CDI), nocturnal polyuria, and primary nocturnal enuresis.
4. Therapeutic Indications & Evidence-Supported Uses
- Cabergoline: Hyperprolactinaemia, prolactinoma (pituitary micro/macroadenoma), and inhibition/suppression of physiological lactation
- Desmopressin: Central Diabetes Insipidus (CDI), nocturnal polyuria, and primary nocturnal enuresis
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Cabergoline: Hyperprolactinaemia: Start 0.25 mg PO TWICE weekly (e.g., Monday & Thursday), titrate monthly to 0.5–1 mg twice weekly; Lactation Inhibition: 1 mg (two 0.5 mg tabs) single dose on Day 1 postpartum. Desmopressin: CDI: 0.1–0.2 mg PO BD–TDS; Enuresis: 0.2 mg PO (or 120 mcg Melt) at bedtime
Administration & Meal Timing: Take Cabergoline WITH dinner or at bedtime with food. For Desmopressin in nocturnal enuresis/polyuria: RESTRICT fluid intake from 1 hour BEFORE until 8 hours AFTER the bedtime dose! | Cabergoline: Twice Weekly (e.g., Mon & Thu evening) with food. Desmopressin: Bedtime (Enuresis) or BD–TDS (CDI)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Desmopressin is renally cleared — CONTRAINDICATED if CrCl <50 mL/min! Hepatic: Reduce Cabergoline in Child–Pugh C cirrhosis
Renal: Desmopressin is renally cleared — CONTRAINDICATED if CrCl <50 mL/min! Hepatic: Reduce Cabergoline in Child–Pugh C cirrhosis
Renal: Desmopressin is renally cleared — CONTRAINDICATED if CrCl <50 mL/min! Hepatic: Reduce Cabergoline in Child–Pugh C cirrhosis
7. Contraindications, Precautions & High-Risk Warnings
- Cabergoline CONTRAINDICATED in pre-eclampsia/postpartum hypertension, cardiac valvulopathy, and pulmonary/pericardial/retroperitoneal fibrosis. Desmopressin CONTRAINDICATED in habitual/psychogenic polydipsia, baseline Serum Na+ <135 mEq/L, moderate-to-severe CKD (CrCl <50 mL/min), SIADH, and heart failure!
Key Clinical Precautions: Renal: Desmopressin is renally cleared — CONTRAINDICATED if CrCl <50 mL/min! Hepatic: Reduce Cabergoline in Child–Pugh C cirrhosis
8. Adverse Effects Profile
- Cabergoline: Nausea, postural dizziness, headache, constipation. Desmopressin: Headache, hyponatraemia, nausea
- Cabergoline: Postural syncope, fibrotic cardiac valvulopathy, impulse-control disorders. Desmopressin: SEVERE WATER INTOXICATION & HYPONATRAEMIC SEIZURES/COMA (Na+ <125 mEq/L) if fluids are not restricted!
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Cabergoline: D2 antagonists (Domperidone, Metoclopramide, Levosulpiride, Risperidone, Haloperidol) directly oppose Cabergoline and raise prolactin! Macrolides increase Cabergoline levels
- Desmopressin: SSRIs, Carbamazepine, Oxcarbazepine, Thiazides, and NSAIDs markedly increase hyponatraemia risk!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: For Cabgolin: take ONLY twice a week (not daily!) with dinner; for Minirin: stop drinking fluids 1 hour before bedtime until next morning to prevent dangerous brain swelling/low sodium, and hold Minirin during acute vomiting/diarrhoea or fever
- Meal & Clock Timing Instruction: Take Cabergoline WITH dinner or at bedtime with food. For Desmopressin in nocturnal enuresis/polyuria: RESTRICT fluid intake from 1 hour BEFORE until 8 hours AFTER the bedtime dose! (Cabergoline: Twice Weekly (e.g., Mon & Thu evening) with food. Desmopressin: Bedtime (Enuresis) or BD–TDS (CDI))
- Missed Dose Protocol: Cabergoline: Take within 1–2 days if missed. Desmopressin: Never double dose
- Geriatric Dispensing Pearl: AVOID Desmopressin for nocturia in older adults >=65 years (AGS Beers 2023 & STOPP v3: very high incidence of severe life-threatening hyponatraemia!)
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Cabergoline Tablets: 0.25 mg, 0.5 mg. Desmopressin Tablets: 0.1 mg (100 mcg), 0.2 mg (200 mcg); Sublingual Melt: 60 mcg, 120 mcg; Nasal Spray: 10 mcg/spray
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 06 [6.12] (p. 77)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [6.8]-C36 Fludrocortisone Acetate — Oxazoline Glucocorticoid & Potent Synthetic Mineralocorticoid (Sc
- [6.9]-C37 Medroxyprogesterone Acetate — Oral Synthetic Progestogens & Retroprogesterone (Schedule H | NLE
- [6.9]-C38 Dydrogesterone — Oral Synthetic Progestogens & Retroprogesterone (Schedule H | NLE
- [6.9]-CMP39 Natural Micronized Progesterone IP — Oral Synthetic Progestogens & Retroprogesterone (Schedule H | NLE
